A new peer reviewed paper is drawing attention in the world of cancer research by exploring whether existing, low-cost drugs could have roles in future cancer therapies. It comes from one of the world’s highly credentialed and accomplished critical care physicians, Dr. Paul Marik.
Published in the Journal of Orthomolecular Medicine, the paper titled ‘Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol’ was authored by researchers including Ilyes Baghli, Pierrick Martinez, and Dr. Paul Marik, along with other collaborators.
The paper examines a combination approach involving repurposed medications such as ivermectin, mebendazole, and fenbendazole, alongside nutritional and metabolic strategies. The authors explore the idea that targeting cancer metabolism, mitochondrial function, inflammation, and cancer stem cell pathways may offer new avenues for treatment.
Instead of developing entirely new medicines from scratch, researchers are investigating whether existing medications, already known in other medical contexts, may have overlooked anti-cancer properties.
The next important step would be rigorous human studies to determine whether these approaches actually improve outcomes for patients.
The future of cancer care will depend not only on discovering new treatments, but also on having the curiosity and scientific rigor to explore unconventional possibilities while following the evidence. Sadly, the pharmaceutical industry may frown upon such methods as they are cheap and highly accessible.